On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
Open Access
- 3 November 2022
- journal article
- research article
- Published by Georg Thieme Verlag KG in TH Open
- Vol. 06 (04) , e354-e364
Abstract
Background Direct oral anticoagulants (DOACs) provide a safe, effective alternative to vitamin K antagonists (VKAs) for venous thromboembolism (VTE) treatment, as shown via intention-to-treat comparative effectiveness analysis. However, on-treatment analysis is imperative in observational studies because anticoagulation choice and duration are at investigators' discretion. Objectives The aim of the study is to compare the effectiveness of DOACs and VKAs on 12-month outcomes in VTE patients using on-treatment analysis. Methods The Global Anticoagulant Registry in the FIELD - VTE (GARFIELD-VTE) is a world-wide, prospective, non-interventional study observing treatment of VTE in routine clinical practice. Results In total, 8,034 patients received VKAs (n = 3,043, 37.9%) or DOACs (n = 4,991, 62.1%). After adjustment for baseline characteristics and follow-up bleeding events, and accounting for possible time-varying confounding, all-cause mortality was significantly lower with DOACs than VKAs (hazard ratio: 0.58 [95% confidence interval 0.42–0.79]). Furthermore, patients receiving VKAs were more likely to die of VTE complications (4.9 vs. 2.2%) or bleeding (4.9 vs. 0.0%). There was no significant difference in rates of recurrent VTE (hazard ratio: 0.74 [0.55–1.01]), major bleeding (hazard ratio: 0.76 [0.47–1.24]), or overall bleeding (hazard ratio: 0.87 [0.72–1.05]) with DOACs or VKAs. Unadjusted analyses suggested that VKA patients with active cancer or renal insufficiency were more likely to die than patients treated with DOAC (52.51 [37.33–73.86] vs. 26.52 [19.37–36.29] and 9.97 [7.51–13.23] vs. 4.70 [3.25–6.81] per 100 person-years, respectively). Conclusion DOACs and VKAs had similar rates of recurrent VTE and major bleeding. However, DOACs were associated with reduced all-cause mortality and a lower likelihood of death from VTE or bleeding compared with VKAs.Keywords
This publication has 26 references indexed in Scilit:
- Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trialsBlood, 2014
- Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trialThe Lancet, 2014
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised TrialsPLOS Medicine, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Model Selection, Confounder Control, and Marginal Structural ModelsThe American Statistician, 2004
- Intent-to-Treat Analysis versus As-Treated AnalysisDrug Information Journal, 1996